Search

Your search keyword '"Dirks, Peter"' showing total 459 results

Search Constraints

Start Over You searched for: Author "Dirks, Peter" Remove constraint Author: "Dirks, Peter" Database Unpaywall Remove constraint Database: Unpaywall
459 results on '"Dirks, Peter"'

Search Results

1. Assessment of MR blood-oxygen-level-dependent (BOLD) cerebrovascular reactivity under general anesthesia in children with moyamoya

2. PRMT5 is required for full-lengthHTTexpression by repressing multiple proximal intronic polyadenylation sites

3. Supplementary Figures S1-S5 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium

4. Supplementary Figures S1-S5 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium

5. Abstract WP219: Diffusion Weighted Imaging Characteristics in Deep White and Gray Matter Structures in Pediatric Patients With Moyamoya Disease

7. Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium

8. Pan-cancer ion transport signature reveals functional regulators of glioblastoma aggression

13. CNSC-44. BIOLOGICAL PATTERN DISCOVERY IN GLIOBLASTOMA

15. A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma

16. Pediatric Moyamoya Revascularization Perioperative Care: A Modified Delphi Study

19. macroH2A2 antagonizes epigenetic programs of stemness in glioblastoma

23. Pan-cancer analysis of the ion permeome reveals functional regulators of glioblastoma aggression

24. Supplementary Table 1 - Cell line information from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

25. Supplementary Figure 1 - PARP1 protein is expressed in pHGA and DIPG patient samples from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

26. Supplementary Figure 4 - Niraparib induces growth arrest in SJG2 and SF188 cells. from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

27. Supplemental Figure Legends from ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

28. Data from ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

29. Supplemental Figures 1 - 9 from ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

30. Supplementary Figure 1 - PARP1 protein is expressed in pHGA and DIPG patient samples from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

31. Supplementary Figure 3 - Niraparib treatment increases DNA damage and decreases proliferation. from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

32. Supplemental Methods from ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

33. Supplementary Figure Legends from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

34. Supplemental Table 1 from ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

35. Supplementary Figure 2 - Cell viability assay for pediatric brain tumour lines exposed to the indicated concentrations of Veliparib, Olaparib, or Niraparib. from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

36. Supplementary Figure 5 - Low doses of Niraparib reduce the rate of DNA repair and sensitize cells to ionizing radiation from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

37. Supplementary Figure Legends from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

38. Supplemental Figures 1 - 9 from ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

39. Supplemental Figure Legends from ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

40. Supplementary Figure 5 - Low doses of Niraparib reduce the rate of DNA repair and sensitize cells to ionizing radiation from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

41. Data from ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

42. Supplementary Table 1 - Cell line information from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

43. Supplemental Table 1 from ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

44. Supplemental Methods from ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

45. Supplementary File 1 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma

46. CCR Translation for This Article from Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition

47. Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes

48. Supplementary File 2 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma

49. Supplementary Data from Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition

50. Supplementary Data from BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma

Catalog

Books, media, physical & digital resources